We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$539M
AUM Growth
+$38.3M
Cap. Flow
+$82.7M
Cap. Flow %
15.36%
Top 10 Hldgs %
44.1%
Holding
265
New
51
Increased
68
Reduced
40
Closed
62

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$17M
2
SWTX
SpringWorks Therapeutics
SWTX
+$9.56M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$8.73M
4
SHY icon
iShares 1-3 Year Treasury Bond ETF
SHY
+$8.5M
5
SEPN
Septerna Inc
SEPN
+$8.23M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$11.4M
2
ASND icon
Ascendis Pharma A/S
ASND
+$10M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$6.65M
4
EDR
Endeavor Group Holdings, Inc.
EDR
+$6.59M
5
SNY icon
Sanofi
SNY
+$4.8M

Sector Composition

Rank Sector Weight
1 Healthcare 78.09%
2 Financials 3.23%
3 Technology 0.19%
4 Consumer Discretionary 0.05%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLYM
151
Climb Bio
CLYM
$802M
$146K 0.03%
119,320
+71,195
+148% +$115K
AVXL icon
152
Anavex Life Sciences
AVXL
$310M
$139K 0.03%
16,221
– –
IMNM icon
153
Immunome
IMNM
$2.83B
$135K 0.03%
+20,000
New +$192K
SLDB icon
154
Solid Biosciences
SLDB
$826M
$128K 0.02%
34,479
-114,424
-77% -$490K
SPRB
155
Spruce Biosciences
SPRB
$129M
$117K 0.02%
5,383
– –
ACHV icon
156
Achieve Life Sciences
ACHV
$683M
$115K 0.02%
43,173
+30,000
+228% +$93.3K
YARW
157
Yarrow Bioscience, Inc. Common Stock
YARW
$111M
$111K 0.02%
+1,408
New +$173K
PMVP icon
158
PMV Pharmaceuticals
PMVP
$63.5M
$110K 0.02%
101,008
– –
ENGN icon
159
enGene Therapeutics
ENGN
$121M
$107K 0.02%
+23,799
New +$148K
AQN icon
160
Algonquin Power & Utilities
AQN
$4.42B
$103K 0.02%
20,000
-20,000
-50% -$94.4K
CASI
161
DELISTED
CASI Pharmaceuticals
CASI
$102K 0.02%
47,420
+1,100
+2% +$2.69K
CLOV icon
162
Clover Health Investments
CLOV
$2.51B
$102K 0.02%
28,300
+5,000
+21% +$20.1K
BOLT icon
163
Bolt Biotherapeutics
BOLT
$7.78M
$98K 0.02%
12,248
– –
STTK icon
164
Shattuck Labs
STTK
$694M
$97.1K 0.02%
+102,156
New +$126K
UPB
165
Upstream Bio Inc
UPB
$395M
$91.8K 0.02%
+15,000
New +$143K
AVTX icon
166
Avalo Therapeutics
AVTX
$983M
$80.1K 0.01%
+10,000
New +$75.8K
INZY
167
DELISTED
Inozyme Pharma
INZY
$79.9K 0.01%
87,799
+11,500
+15% +$15.9K
RXRX icon
168
Recursion Pharmaceuticals
RXRX
$1.72B
$79.3K 0.01%
15,000
– –
BCRX icon
169
BioCryst Pharmaceuticals
BCRX
$2.4B
$75K 0.01%
10,000
-25,000
-71% -$202K
LYRA
170
DELISTED
LYRA THERAPEUTICS INC
LYRA
$67.3K 0.01%
10,664
– –
PHAT icon
171
CALL
Phathom Pharmaceuticals
PHAT
$692M
$63.3K 0.01%
10,100
– –
ADGM
172
Adagio Medical Holdings
ADGM
$15.2M
$61.8K 0.01%
76,757
– –
NXTC icon
173
NextCure
NXTC
$23.8M
$57.6K 0.01%
10,001
– –
TNGX icon
174
Tango Therapeutics
TNGX
$4.41B
$56.6K 0.01%
+41,346
New +$102K
ELDN icon
175
Eledon Pharmaceuticals
ELDN
$285M
$56.3K 0.01%
16,600
+600
+4% +$2.47K
5 6
7
8 9

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, ADAR1 Capital Management held 265 positions worth $539M, up 7.7% from $500M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

ADAR1 Capital Management deployed $82.7M of net new capital in Q1 2025, opening 51 new positions and adding to 68 existing holdings. Its largest new stake was SpringWorks Therapeutics: 207,778 shares worth $9.17M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 78% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was BridgeBio Pharma, an estimated $11.4M trimmed.

  • ADAR1 Capital Management's largest Q1 2025 buy was SpringWorks Therapeutics: 207,778 shares worth $9.17M.
  • ADAR1 Capital Management added most to Keros Therapeutics in Q1 2025, an estimated $17M increase.
  • ADAR1 Capital Management's biggest Q1 2025 reduction was BridgeBio Pharma, cutting an estimated $11.4M.
  • ADAR1 Capital Management fully exited Endeavor Group Holdings, Inc. in Q1 2025, selling an estimated $6.59M.
  • ADAR1 Capital Management's ten largest holdings make up 44% of its $539M portfolio in Q1 2025.
  • ADAR1 Capital Management opened 51 new positions and closed 62 in Q1 2025.
  • ADAR1 Capital Management's portfolio value rose 7.7% quarter-over-quarter to $539M.

Based on ADAR1 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.